HomeCompareRMD vs PKI

RMD vs PKI: Dividend Comparison 2026

RMD yields 1.06% · PKI yields 0.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMD wins by $12.0K in total portfolio value
10 years
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →

Portfolio growth — RMD vs PKI

📍 RMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMDPKI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMD + PKI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMD pays
PKI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
At 15% tax rate, RMD beats the other by $2,795.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMD + PKI for your $10,000?

RMD: 50%PKI: 50%
100% PKI50/50100% RMD
Portfolio after 10yr
$25.7K
Annual income
$1,644.13/yr
Blended yield
6.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PKI right now

RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMD buys
0
PKI buys
0
No recent congressional trades found for RMD or PKI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMDPKI
Forward yield1.06%0.24%
Annual dividend / share$2.33$0.28
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR35.9%-50%
Portfolio after 10y$31.7K$19.7K
Annual income after 10y$3,288.25$0.02
Total dividends collected$10.4K$24.00
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$295.88$166.57

Year-by-year: RMD vs PKI ($10,000, DRIP)

YearRMD PortfolioRMD Income/yrPKI PortfolioPKI Income/yrGap
1← crossover$10,844$143.91$10,712$12.15+$132.00RMD
2$11,801$198.21$11,468$6.08+$333.00RMD
3$12,901$273.96$12,274$3.04+$627.00RMD
4$14,185$380.39$13,135$1.52+$1.1KRMD
5$15,709$531.20$14,055$0.76+$1.7KRMD
6$17,556$747.16$15,039$0.38+$2.5KRMD
7$19,845$1,060.53$16,092$0.19+$3.8KRMD
8$22,757$1,522.63$17,218$0.10+$5.5KRMD
9$26,567$2,217.64$18,424$0.05+$8.1KRMD
10$31,715$3,288.25$19,713$0.02+$12.0KRMD

RMD vs PKI: Complete Analysis 2026

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →
📬

Get this RMD vs PKI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMD vs SCHDRMD vs JEPIRMD vs ORMD vs KORMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.